Abstract: Objective To investigate the inhibition of tumor growth and vascular endothelial growth factor （VEGF） expression of bevacizumab in rats with diethylnitrosamine-induced hepatic neoplasma. Methods 30 SD rats were randomly divided into control，model and bevacizumab-intervened groups. The combination of tetrachloromethane and diethylnitrosamine（DEN） were used to establish liver cancer in rats. The bevacizumab or saline was given intraperitoneally for 12 weeks. The sera and liver tissues were obtained. The liver weights， surface carcinoma nodule numbers，canceration rates and liver index were detected. The VEGF expression was stained immunohistochemically. Results The liver weights，surface carcinoma nodule numbers，canceration rates and liver index were（17.51±2.53） g，（6.86±0.82），30% and（4.10±0.79） in the bevacizumab-intervened group， significantly lower than those in the model group[（23.71±3.01），（21.91±2.75），100.0% and（5.90±1.01）， respectively，P<0.05]；serum AST，ALT and TBIL levels were（101.58±19.83） IU/L，（241.52±36.58） IU/L and （62.93±3.03） μmol/L in the bevacizumab-intervened group，significantly lower than those in the model group（P<0.05）；Liver pathological examination showed that the liver injures，canceration and VEGF expression were alleviated in the bevacizumab-intervened group. Conclusions The application of Bevacizumab has a good inhibitory effect on DEN-induced canceration in rats，which warrants further study.

Key words: Hepatoma, Diethylnitrosamine, Bevacizumab, Rats